BIRC5 and non-small cell lung carcinoma: Unlike other IAPs, BIRC5 expresses intensely in most tumors, including LUAD and LUSC [55], and it could serve as a predictive biomarker for NSCLC, especially for LUAD [56], but does not express or only expresses at low levels in most normally differentiated tissues [57], and down-regulated BIRC5 was positively associated with NSCLC survival time [58].